Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin's Lymphoma in Japan
Stock Information for MEI Pharma Inc.
Loading
Please wait while we load your information from QuoteMedia.